“The Strategic Partnership III Award reviews are in: Asterias Biotherapeutics / BioTime will get $14 million to restart spinal cord injury trial with GRNOPC1.”
Our thanks to the anonymous reader for pointing out the information on the award.
(The day following publication of this item, Asterias reported clearing the first safety hurdle on the trial.)
(Okarma left Asterias in April. An earlier version of this item said Okarma was still head of the company.)